IGF1 and metastatic colorectal cancer: In another study, chemorefractory wild-type KRAS metastatic colorectal cancer patients harboring the IGF1 rs2946834 variant A/A genotype had a significantly higher response rate to cetuximab (50%) compared to those with the A/G genotype (0%) [21].